The developer of a rapid point-of-care diagnostics tests, DCN Dx declared the appointment of John L. Tokinson, Ph.D. as its Chief business development Officer, welcoming him on board. Dr. Tonkinson likely to execute a strategic growth plan to help sustain its acclaimed recognition for offering point- of care diagnostic tests. Dr. Tonkinson pursued his Ph.D. in Biochemistry and Molecular Biophysics from Columbia University and completed a Post-Doctoral Fellowship in Cancer Drug Discovery at Eli Lilly and Co.
He also possesses 15 years of expertise at several biotechnology companies focusing on building teams and establishing business models conveying technologies to wider markets thus broadening its base. He has also led an R&D team at S&S bioscience for lateral flow assays.
Brendan O’Farrell, President of DCN Dx stated “His background and experience in science and in business is a perfect fit with DCN as we grow to the next level. We expect that his diverse background working with small and large companies in all areas of scientific product development and commercialization will be a strong asset.”
Image Source: DCN Dx, Inc.